Tavo Biotherapeutics
PrivateLast Round
Series A
Jun 2, 2026
Total Funding Raised
$29.2M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Tavo Biotherapeutics operates in Healthcare & Life Sciences and is based in Laguna Beach, California. Its latest recorded funding round was a Series A round in June 2026.
Tavo Biotherapeutics is a biopharmaceutical company developing novel therapeutics for ophthalmic diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B2C
Customer Profile
Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Tavo Biotherapeutics Comparables
Compare Tavo Biotherapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Perceive Pharma | 88% | |
| RevOpsis Therapeutics | 82% | |
| Nicox S.A. | 72% |
For institutional investors. Book with your work email.
Tavo Biotherapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Jun 2, 2026 | ||||
| Grant | Sep 1, 2024 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Tavo Biotherapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| U.S. Department of Health and Human Services | Grant |
| Tau Capital | Series A, Seed |
| NIH RADx | Grant |
| Tennessee Technology Development Corporation | Grant |
| Pureos Bioventures | Series A |
| Polaris Partners | Series A |
| National Eye Institute | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 25, 2026
Grew 27% QoQ, from 11 to 14 employees.
- Jul 27, 2026
Monthly visitors increased 58% MoM.
For institutional investors. Book with your work email.
Tavo Biotherapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Tavo Biotherapeutics's valuation, stock price, and market status.
Is Tavo Biotherapeutics a public or private company?
Tavo Biotherapeutics is a private company.
What is the current stock price of Tavo Biotherapeutics?
Tavo Biotherapeutics is a private company, so its shares have no public market price. Caplight tracks Tavo Biotherapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Tavo Biotherapeutics worth (valuation)?
Valuation information for Tavo Biotherapeutics is not publicly available.
Can I buy Tavo Biotherapeutics stock?
Tavo Biotherapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Tavo Biotherapeutics's last funding round?
Tavo Biotherapeutics's most recent funding round was Series A on June 2, 2026.
Who are the main investors in Tavo Biotherapeutics?
Key investors in Tavo Biotherapeutics include Pureos Bioventures.
Will Tavo Biotherapeutics IPO soon?
No public IPO plans have been announced for Tavo Biotherapeutics.
How can I track Tavo Biotherapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Tavo Biotherapeutics's shares on secondary markets.